We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Irish devicemaker Covidien said Tuesday it is halting development on the OneShot renal denervation system, marking yet another blow to a technology once seen as the future of hypertension treatment. Read More
Even as more and more healthcare is moving into the home, manufacturers and other stakeholders remain ill-prepared to serve that patient population. That’s the conclusion of a new report by the Association for the Advancement of Medical Instrumentation. Read More
Medtronic’s Symplicity renal denervation system for the treatment of uncontrolled hypertension failed to meet a primary endpoint in its U.S. pivotal trial, putting a surprising halt on a technology that had been expected to be a major revenue driver. Read More
Medtronic is enrolling patients in the VICTORY AF trial to evaluate the safety of its investigational Phased RF system for atrial fibrillation. Read More
The promising new hypertension treatment known as renal denervation is safe in the short to medium term, but more safety information is needed before conclusions can be drawn about its long-term benefits versus standard care in treating treatment-resistant hypertension, according to a rapid assessment by the European Network for Health Technology Assessment. Read More